BridgeBio Pharma, Inc. Purchase Agreement January 25, 2021BridgeBio Pharma, Inc. • January 26th, 2021 • Pharmaceutical preparations • New York
BridgeBio Pharma, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $650,000,000 principal amount of its 2.25% Convertible Senior Notes due 2029 (the “Underwritten Securities”) and, at the option of the Initial Purchasers, up to an additional $97,500,000 principal amount of its 2.25% Convertible Senior Notes due 2029 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 2.25% Convertible Senior Notes due 2029 granted to the Initial Purchasers in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into shares (the “Underlying Securities”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), or a combina
